Find us at PEGS Boston Summit in Booth #322!

We are delighted to announce that we are traveling back to Boston on May 2-6. For the first time in over 2 years, more than 100 exhibitors will be returning to PEGS Boston, and finally, we all meet face to face again.

We are also proud to announce that we will present our newest addition to the iLite® Portfolio with Assay Ready Cells of ADCP Effector cells, CD3 Effector cells and CD19 Target cells.

Meet us there and listen to these latest innovations and improvements and learn from our long experience in assay development, bioanalysis, and clinical diagnostics which makes us an ideal partner for pharma, biotech, and CROs.

Find us at PEGS Boston Summit in Booth #322!

We are delighted to announce that we are traveling back to Boston on May 2-6. For the first time in over 2 years, more than 100 exhibitors will be returning to PEGS Boston, and finally, we all meet face to face again.

We are also proud to announce that we will present our newest addition to the iLite® Portfolio with Assay Ready Cells of ADCP Effector cells, CD3 Effector cells and CD19 Target cells.

Meet us there and listen to these latest innovations and improvements and learn from our long experience in assay development, bioanalysis, and clinical diagnostics which makes us an ideal partner for pharma, biotech, and CROs.

Don't miss our scientific agenda!

SCIENTIFIC PRESENTATION 

"Quantification of bispecific antibody-mediated T-cell activation with engineered CD3 effector and tailored target cells"

Listen to Svars' Chief Technolgy Officer present the newest addition to the iLite portfolio - CD3 effector cells and tailored CD19 target cells and hear him explain how these cells can aid in the development of bi-specific CD3 signaling therapeutic antibodies. 

PRESENTATION TRACK: Characterization for Novel Biotherapeutics

TIME: Tuesday, May 3, 10:15 am EDT (16:15 CEST)

PRESENTER: Michael Schwenkert, Ph.D. - Chief Technology Officer

Bispecific antibodies efficiently trigger T-cells mediated cytotoxicity, and many T-cell-engaging biopharmaceuticals are in clinical development. Current analytical methods measuring T-cell activation are not optimal. Here we showcase an improved bioassay platform for reliable assessment of T-cell activation using CD3xCD19. Effector T-cells carry a reporter gen downstream the CD3 signaling cascade and a pair of engineered target cells is used as antigen-positive/-negative control

 

We will be present throughout the event so please don´t hesitate to come and discuss this or other topics of interest with us!

POSTER PRESENTATIONS

We will be showcasing our Fc Effector cells - iLite ADDC and our new iLite ADCP Effector cells in two posters during the poster presentation.  Find out how our Fc-effector package, with uniquely engineered Effector cells and corresponding Target cells can assist you in your drug development

PRESENTER: Therese Segerstein, Portfolio Director


"Quantification of ADCP Activity of Therapeutic Antibodies Using Engineered Effector Cells and Target Cells"

Many therapeutic antibodies use ADCC and ADCP as key mechanisms of action. We have developed a method for quantifying ADCP activity based on a novel iLite effector cell and genetically engineered target cells. These assays offer significantly improved dynamic range compared to assays from a leading competitor, while at the same time offering excellent sensitivity and serum tolerance.

"Development of a Highly Sensitive ADCC iLite® Reporter Gene Assay with True MoA-Reflecting Properties"

We have created a sensitive proprietary iLite ADCC assay, consisting of a gene-reporter effector cell line, combined with custom-engineered target cell lines for commonly used receptors. The iLite ADCC assays offer superior sensitivity and dynamic range compared to assays from a leading competitor and correlate well with a PBMC-mediated assay, indicating that the iLite assay can fully capture the ADCC MoA.

Come and say hi!

Visit our Booth #322!

Stop by our booth where you will meet our team of experts and learn more about how we can our help streamline your drug development and your bioanalytical projects!

We look forward to meeting you!

Make sure to catch us at the event!

Book a meeting today already, to let us help  with your bioanalytical acceleration in your drug development projects!